|
Phase I study of the antibody-drug conjugate ABBV-321 in patients with non-small cell lung cancer and squamous head and neck cancer with overexpression of the epidermal growth factor receptor. |
|
|
Consulting or Advisory Role - EMD Serono; Foundation Medicine; Tempus |
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; Pfizer |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - EMD Serono |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Speakers' Bureau - Eisai; Merck Serono; Merck Serono |
Research Funding - AbbVie |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
Patents, Royalties, Other Intellectual Property - AbbVie employee holds patents |
Travel, Accommodations, Expenses - Abbvie |
|
|
Consulting or Advisory Role - ArQule; Bayer |
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Bayer (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst) |